Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23520759 | 1.00 | KMT2A (0.39) | KMT2AMEN1ACHEGAANPSR1 | |
| SCHEMBL29755156 | 0.86 | KMT2A (0.43) | KMT2AMEN1ACHEGAANPSR1 | |
| SCHEMBL20792450 | 0.86 | KMT2A (0.52) | KMT2AMEN1GAANPSR1CES2 | |
| SCHEMBL29180795 | 0.86 | KMT2A (0.43) | KMT2AMEN1ACHEGAANPSR1 | |
| SCHEMBL21132427 | 0.86 | KMT2A (0.52) | KMT2AMEN1GAANPSR1CES2 | |
| SCHEMBL29949168 | 0.86 | KMT2A (0.52) | KMT2AMEN1GAANPSR1CES2 | |
| SCHEMBL21133184 | 0.86 | KMT2A (0.43) | KMT2AMEN1ACHEGAANPSR1 | |
| SCHEMBL22321401 | 0.86 | KMT2A (0.52) | KMT2AMEN1GAANPSR1CES2 | |
| SCHEMBL21133185 | 0.86 | KMT2A (0.43) | KMT2AMEN1ACHEGAANPSR1 | |
| SCHEMBL30839869 | 0.83 | KMT2A (0.40) | KMT2AMEN1ACHEGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | KMT2A 3346/4885MEN1 128/4885ACHE 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.